Home›Stock Screener›Accretion Pharmaceuticals›Financial Statements

Accretion Pharmaceuticals Complete Financial Statements

2 Years of Data
2025 - 2024

In FYNone, Accretion Pharmaceuticals (ACCPL) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 12.1% and ROE of 46.7%. Full financial statements from FY2024 to FY2025 (2 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review ACCPL price earnings ratio to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 12.07% 2025 data
EBITDA Margin 20.69% 2025 data
Operating Margin 21.00% 2025 data
Return on Assets 17.50% 2025 data
Return on Equity 46.67% 2025 data

Balance Sheet Ratios

Current Ratio 34.00 2025 data
Equity Ratio 37.50% 2025 data
Asset Turnover 1.45 2025 data

ACCPL Revenue, Net Profit & EBITDA — Year-on-Year Growth

ACCPL YoY (March 2025 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. Explore Accretion Pharmaceuticals intrinsic worth to estimate fundamental worth using multiple valuation models.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+48.1%
Year-over-Year
Equity Growth
+150.0%
Year-over-Year
Operating Cash Flow Growth
+150.0%
Year-over-Year
Investing Cash Flow Growth
+66.7%
Year-over-Year
Financing Cash Flow Growth
-123.5%
Year-over-Year

ACCPL Income Statement — Revenue, EBITDA & Net Profit

Accretion Pharmaceuticals revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 12.1%. For live price, earnings ratios and company overview, see Accretion Pharmaceuticals share price screener.

Periods ₹ Crores
Particulars None March 2025 March 2024
Revenue 0 58 13
Expenses 0 46 11
EBITDA 0 12 3
Operating Profit Margin % 0.00% 21.00% 19.00%
Depreciation 0 1 0
Interest 0 1 0
Profit Before Tax 0 10 2
Tax 0 3 1
Net Profit 0 7 2
Earnings Per Share (₹) 0.00 8.48 1.96

ACCPL Balance Sheet — Assets, Liabilities & Shareholders' Equity

ACCPL total assets ₹40 Cr, total equity ₹15 Cr, total liabilities ₹ Cr (2025) — ROE 46.7%.

Years Annual Data ₹ Crores
Particulars 2025 2024
ASSETS
Total Assets 40 27
Current Assets 34 22
Fixed Assets 6 5
Capital Work in Progress 0 0
Investments 0 0
Other Assets 34 22
LIABILITIES
Total Liabilities
Current Liabilities 1 7
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 15 6
Share Capital 8 4
Reserves & Surplus 7 2

ACCPL Cash Flow Statement — Operating, Investing & Financing

Accretion Pharmaceuticals operating cash flow ₹6 Cr, investing ₹-2 Cr, financing ₹-4 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024
Operating Activities 6 -12
Investing Activities -2 -6
Financing Activities -4 17
Net Cash Flow 0 0